| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 147, 1567-1574, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
DG Jamieson, DC Usher, DJ Rader and E Lavi
Division of Neuropathology, University of Pennsylvania School of Medicine, Philadelphia 19104-6079, USA.
Atherosclerosis is the leading cause of death and serious morbidity in economically developed societies through its sequelae of coronary artery and cerebrovascular disease. The causes and mechanisms of atherosclerosis are still largely unknown. Serum levels of a lipoprotein, Lp(a), have been shown, in retrospective and some prospective clinical studies, to be associated with increased risk of myocardial and cerebral infarction. The active part of Lp(a), apo(a), has > 80% homology with plasminogen; thus it may competitively inhibit the thrombolytic action of plasminogen and enhance thrombogenesis. Lp(a) has been shown to be deposited in the vascular wall of the aorta and coronary vessels, but its presence in the cerebral vessels has not yet been shown. Autopsy specimens of vessels of the circle of Willis from 23 patients were examined for degree of atherosclerosis and deposition of apo(a) by immunohistochemistry with apo(a)-specific monoclonal antibodies. The amount of apo(a) deposition in cerebral vessels correlated well with the degree of cerebral atherosclerosis. Arterial deposition of apo(a) was found entirely within the endothelial cell and subendothelial cell layers. There was no staining within the media and adventitia, with the exception of staining within the endothelial cells of the vasa vasorum. Correlation between the morphology of apo(a) deposition and plaque stage was found suggesting that detection of apo(a) in endothelial cells is an early event in the development of the atherosclerotic plaque of cerebral vessels.
This article has been cited by other articles:
![]() |
J. F. Arenillas, C. A. Molina, P. Chacon, A. Rovira, J. Montaner, P. Coscojuela, E. Sanchez, M. Quintana, and J. Alvarez-Sabin High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis Neurology, July 13, 2004; 63(1): 27 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Das Sarma, L. Fu, J. C. Tsai, S. R. Weiss, and E. Lavi Demyelination Determinants Map to the Spike Glycoprotein Gene of Coronavirus Mouse Hepatitis Virus J. Virol., October 1, 2000; 74(19): 9206 - 9213. [Abstract] [Full Text] |
||||
![]() |
G. Lippi and G. Guidi Lipoprotein(a): from ancestral benefit to modern pathogen? QJM, February 1, 2000; 93(2): 75 - 84. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Syrovets, J. Thillet, M. J. Chapman, and T. Simmet Lipoprotein(a) Is a Potent Chemoattractant for Human Peripheral Monocytes Blood, September 1, 1997; 90(5): 2027 - 2036. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A.-R. Higazi, E. Lavi, K. Bdeir, A. M. Ulrich, D. G. Jamieson, D. J. Rader, D. C. Usher, W. Kane, T. Ganz, and D. B. Cines Defensin Stimulates the Binding of Lipoprotein (a) to Human Vascular Endothelial and Smooth Muscle Cells Blood, June 15, 1997; 89(12): 4290 - 4298. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |